Fast MDx
Fast MDx is a social enterprise dedicated to providing affordable, high-throughput molecular diagnostic testing worldwide. Their innovative NGX 124 platform offers fully automated, ultra-fast, and open platform testing solutions that are low-cost, environmentally friendly, and accessible in remote and low-income settings. The company aims to revolutionize early detection of infectious diseases and improve global health outcomes.
Industries
Nr. of Employees
small (1-50)
Products
Automated open molecular diagnostic platform (compact mobile system)
A compact, mobile molecular diagnostic platform integrating automated sealed-sample intake, robotic liquid handling and an ultra-fast multi-channel qPCR thermal cycler with reverse-transcription capability; designed for decentralized, high-throughput testing.
Automated open molecular diagnostic platform (compact mobile system)
A compact, mobile molecular diagnostic platform integrating automated sealed-sample intake, robotic liquid handling and an ultra-fast multi-channel qPCR thermal cycler with reverse-transcription capability; designed for decentralized, high-throughput testing.
Services
No-obligation demonstrations delivered in customer laboratories and placement of pre-production platforms for evaluation and validation.
Testing delivered under a contract where the platform is provided without capital expenditure and tests are charged on a per-test basis; includes support for assay adaptation to the platform.
Technical assistance to adapt customer assays to high-throughput automated protocols to minimise dead volumes and optimise performance.
No-obligation demonstrations delivered in customer laboratories and placement of pre-production platforms for evaluation and validation.
Testing delivered under a contract where the platform is provided without capital expenditure and tests are charged on a per-test basis; includes support for assay adaptation to the platform.
Technical assistance to adapt customer assays to high-throughput automated protocols to minimise dead volumes and optimise performance.
Expertise Areas
- High-throughput molecular diagnostics
- Automated liquid handling and lab-automation integration
- qPCR and RT-PCR testing workflows
- Near-patient and mobile diagnostic deployment
Key Technologies
- Automated liquid handling robotics
- Ultra-fast multi-channel qPCR thermal cycling
- Reverse transcription modules for RNA assays
- Sealed-sample aspiration/sample-cap intake
News & Updates
Richard Lewis, CEO of Fast MDx, spoke at Lab Innovations at the NEC on 30 October 2024 as a case study for Festo automation.
Fast MDx Ltd, a London-based social enterprise, announced their NGX 124 platform's potential to revolutionize early detection and quarantine of infectious diseases.
Fast MDx obtained CE-IVDR mark for their NGX 124 system, a fully automated, high-throughput open molecular diagnostic test system.
LabMedica published an article about the Fast MDx Molecular Diagnostic Test System.
Fast MDx is validating their platform with Public Health Wales, advancing their UKCA and CE-IVDR regulatory approvals.
Fast MDx's NGX 124 platform has obtained the CE-IVDR mark, certifying it for high-throughput molecular diagnostics.
Richard Lewis, CEO of Fast MDx, spoke at Lab Innovations at the NEC on 30 October 2024 as a case study for Festo automation.
Fast MDx Ltd, a London-based social enterprise, announced their NGX 124 platform's potential to revolutionize early detection and quarantine of infectious diseases.
Fast MDx obtained CE-IVDR mark for their NGX 124 system, a fully automated, high-throughput open molecular diagnostic test system.
LabMedica published an article about the Fast MDx Molecular Diagnostic Test System.
Fast MDx is validating their platform with Public Health Wales, advancing their UKCA and CE-IVDR regulatory approvals.
Fast MDx's NGX 124 platform has obtained the CE-IVDR mark, certifying it for high-throughput molecular diagnostics.